Anti-Amyloid Antibodies Market Global Report 2026

The anti-amyloid antibodies market size has grown rapidly in recent years. It will grow from $3.27 billion in 2025 to $3.75 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing global prevalence of Alzheimer’s disease, inadequate effectiveness of symptomatic treatments for neurodegeneration, rising research funding for the amyloid hypothesis, progress in monoclonal antibody technology, and a growing aging population worldwide.

The anti-amyloid antibodies market size is expected to see rapid growth in the next few years. It will grow to $6.54 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to rising approvals of disease-modifying Alzheimer’s therapies, expansion of early diagnostic biomarker screening programs, increasing investments in neuroimmunology research, growing adoption of personalized precision medicine approaches, and advancements in next-generation antibody engineering technologies. Major trends in the forecast period include AI-based biomarker discovery for amyloid-beta aggregation mapping, precision medicine strategies for targeted anti-amyloid antibody therapies, integration of digital health tools for Alzheimer’s disease monitoring and progression tracking, cloud-based clinical trial data analytics for neurodegenerative drug development, and advanced biomanufacturing with scalable monoclonal antibody production platforms.

The increasing prevalence of neurodegenerative disorders is anticipated to drive the expansion of the anti-amyloid antibodies market going forward. Neurodegenerative disorders are long-term medical conditions characterized by the gradual degeneration and loss of nerve cells in the brain and nervous system, resulting in progressive cognitive, behavioral, and motor impairments over time. The prevalence of neurodegenerative disorders is rising due to the rapidly aging global population, as older individuals face a significantly higher risk of developing neurological conditions associated with cognitive decline. Anti-amyloid antibodies assist in managing neurodegenerative diseases by helping to reduce the accumulation of amyloid plaques in the brain, enabling earlier therapeutic intervention and slowing disease progression in affected patients. For instance, in March 2024, according to the Alzheimer’s Association, a US-based nonprofit health organization, by 2030, the number of Americans aged 65 and above living with Alzheimer’s disease is projected to reach 13.8 million by 2060, indicating a significant increase in the prevalence of neurodegenerative disorders over time. Therefore, the rising prevalence of neurodegenerative disorders is driving the growth of the anti-amyloid antibodies market.

Leading companies operating in the anti-amyloid antibodies market are focusing on gaining regulatory approvals for innovative Alzheimer’s disease therapies to expand treatment availability, improve patient outcomes, and strengthen their market presence. Regulatory approvals are official authorizations granted by government health agencies confirming that a product meets required safety, efficacy, and quality standards for market use. For example, in July 2024, Eli Lilly and Company, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Kisunla (donanemab), an anti-amyloid antibody treatment for adults with Alzheimer’s disease. The therapy is intended for patients with early symptomatic Alzheimer’s disease, including mild cognitive impairment and mild dementia stages. It works by targeting and clearing amyloid plaques in the brain, helping slow cognitive and functional decline.

In December 2024, AbbVie Inc., a US-based provider of neuroscience therapies, biologics, monoclonal antibodies, and pharmaceutical treatments for neurological disorders, acquired Aliada Therapeutics for an undisclosed amount. Through this acquisition, AbbVie intended to reinforce its neuroscience research strengths, expand its Alzheimer’s disease pipeline, and advance the development of next-generation anti-amyloid antibody therapies utilizing innovative blood-brain barrier-crossing technology. Aliada Therapeutics is a US-based biotechnology company that offers anti-pyroglutamate amyloid beta (3pE-Aβ) antibodies for the treatment of Alzheimer’s disease and other neurological disorders.

Major companies operating in the anti-amyloid antibodies market are Roche Holding AG, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Eisai Co. Ltd., Prothena Corporation plc, AC Immune SA, Neurimmune AG, SciNeuro Pharmaceuticals, ALZpath Inc., Araclon Biotech S.L., BioArctic AB, Acumen Pharmaceuticals Inc., AstraZeneca plc, Attralus Inc.

North America was the dominant region in the anti-amyloid antibodies market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in anti-amyloid antibodies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-amyloid antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-amyloid antibodies market consists of sales of amyloid-beta-targeting immunotherapies, diagnostic anti-amyloid antibodies, recombinant anti-amyloid antibodies, and investigational Alzheimer’s disease antibody therapeutics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The anti-amyloid antibodies market research report is one of a series of new reports that provides anti-amyloid antibodies market statistics, including anti-amyloid antibodies industry global market size, regional shares, competitors with a anti-amyloid antibodies market share, detailed anti-amyloid antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the anti-amyloid antibodies industry. This anti-amyloid antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.